Pheon is #hiring. Come join a phenomenal group!
Pheon Therapeutics
Biotechnology Research
London, England 2,217 followers
Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range of hard-to-treat cancers.
About us
Pheon Therapeutics is leveraging two decades of ADC experience to build a novel pipeline of next generation ADCs which offer the potential to treat solid tumors and liquid cancers that do not respond to other treatments. Understanding there is no “one size fits all” in engineering ADCs, Pheon takes a methodical approach to ADC development. Using both novel and clinically validated monoclonal antibodies (mAbs) and arming them either with warheads from their proprietary payload platform which boasts a novel mechanism of action or with off-the-shelf linker payload combinations, Pheon is finely attuned to balancing safety and efficacy for each target. Pheon’s lead program exploits a novel target that is highly expressed in a broad range of solid tumors. The lead agent is expected to reach IND within the next 18 months. Backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies, Pheon Therapeutics has a world class, proven leadership team that brings together the best of ADC engineering, clinical strategy and business expertise. The company has state-of-the-art medicinal chemistry laboratories in London (United Kingdom), and a commercial office in Boston (United States).
- Website
-
www.pheontx.com
External link for Pheon Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London, England
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
Lawes Open Innovation Hub
Rothamsted Research
London, England AL5 2JQ, GB
Employees at Pheon Therapeutics
Updates
-
Pheon Therapeutics is pleased to announce 📢 the appointment of accomplished biotech executive, Enoch Kariuki, PharmD, to its Board of Directors as an independent, non-executive director. Dr. Kariuki brings a wealth of executive leadership experience and knowledge in #ADCs, which further strengthens Pheon’s board as the company begins its transition into #clinicaldevelopment, with lead ADC program, PHN-010, targeting patients with advanced #solidtumors. Read more about Dr. Kariuki's experience which will be invaluable as #Pheon continue to push boundaries with its differentiated ADC pipeline in the PR 🗞️, linked in the comments below 👇. #Leadership #PheonTherapeutics #CancerResearch #Oncology
-
-
Pheon Therapeutics reposted this
Pheon is #hiring! Please check out our latest role, Clinical Trial Lead, and send your CVs to careers@pheontx.com. #Recruiting #ClinicalTrialLead
-
Pheon is #hiring! Please check out our latest role, Clinical Trial Lead, and send your CVs to careers@pheontx.com. #Recruiting #ClinicalTrialLead
-
📣 Pheon Therapeutics announces the closing of a $120m Series B financing to fund development of its differentiated #ADC pipeline!
-
-
NEWS ALERT! 📣 We are excited to announce the completion of a $120 million Series B financing to advance our differentiated #ADC pipeline through clinical proof of concept⚕. Our first three assets are aimed at an undisclosed novel target that is highly overexpressed in a wide range of #solidtumors This funding round is led by TCGX, with new investments from BVF PARTNERS, L.P, Lightspeed Venture Partners, and Perceptive Advisors, alongside continued support from Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies, Inc.. As part of this milestone, we welcome Cariad Chester, Managing Partner of TCGX, to our highly experienced board of directors. Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program later this year in a Phase 1 clinical trial! For more details, refer to the press release linked in the comments below.
-
-
Pheon Therapeutics is set to be in San Francisco from 8-11 January at the 42nd Annual J.P. Morgan Healthcare Conference. Please get in touch to schedule a meeting with our CEO, Cyrus Mozayeni and discover more about #Pheon's innovative approach to #ADCs with the potential to improve outcomes for patients facing hard-to-treat cancers. Visit our website: pheontx.com #JPM2024 #PheonTherapeutics #Oncology #Innovation
-
-
We’re #hiring! Please check out our new role here
-
Next week, Pheon Therapeutics CEO Cyrus Mozayeni, and VP of R&D and co-founder Paul Jackson will be in London, attending LSX - partnering for Life Science eXecutives Inv€$tival Showcase and Jefferies London Healthcare Conference from the 13-16 November. CEO, Cyrus Mozayeni will be present at #LSX on the 'Biotech Late Growth' stage on Monday, November 13 at 13.45 GMT and will share insights on #Pheon's pipeline of next-generation #ADCs. Following LSX, the team will be attending the #Jefferies London Healthcare Conference from November 14 - 16, the largest healthcare-dedicated conference in Europe. Please get in touch if you're interested in learning more about Pheon's groundbreaking approach to ADCs with the potential to to improve outcomes for patients facing hard-to-treat cancers. #LSXInvestival #JefferiesHealthcareConference #PheonTherapeutics
-